SalubrisBio parent company Salubris Pharmaceuticals announces partnership with JT Pharmaceuticals (Tokyo, Japan) to commercialize HIF-PH inhibitor enarodustat for the treatment of renal anemia in China:

By: |Published on: Oct 27, 2020|Categories: |